Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07662811 | SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 396 | Shanghai Chest HospitalOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07672223 | A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 570 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 26, 2026 |
| clinicaltrials |
| NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC(TRIBE) | not yet recruiting | Phase 3 | 140 | Fudan UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07656376 | Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 2 / Phase 3 | 465 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07653451 | Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer(ESCC-PT) | not yet recruiting | Phase 2 / Phase 3 | 90 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07633873 | SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） | not yet recruiting | Phase 3 | 500 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07637513 | Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer(PrE0512) | not yet recruiting | Phase 3 | 430 | PrECOG, LLC.OTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07621601 | A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 3 | 494 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07608159 | Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. | not yet recruiting | Phase 3 | 201 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | May 29, 2026 | clinicaltrials |
| NCT07613567 | A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer | not yet recruiting | Phase 3 | 486 | Fujian Cancer HospitalOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | not yet recruiting | Phase 3 | 562 | SWOG Cancer Research NetworkNETWORK | 0 | May 27, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07598318 | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations | not yet recruiting | Phase 2 / Phase 3 | 164 | Sir Run Run Shaw HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07595913 | A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 3 | 240 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07376382 | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC(SYNSTAR-02) | not yet recruiting | Phase 3 | 680 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | May 13, 2026 | clinicaltrials |
| NCT07560358 | Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 204 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07535567 | Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma(NimoBenSeq) | not yet recruiting | Phase 2 / Phase 3 | 386 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT07540390 | GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. | not yet recruiting | Phase 3 | 442 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07537946 | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer | not yet recruiting | Phase 3 | 400 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07524413 | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 514 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07526792 | SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | not yet recruiting | Phase 3 | 406 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07477808 | Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 116 | Hunan Province Tumor HospitalOTHER | 0 | Mar 23, 2026 | clinicaltrials |
| NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy(PLANET) | not yet recruiting | Phase 3 | 1,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT07483996 | Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer(CRYSTAL) | not yet recruiting | Phase 3 | 938 | Franciscus Gasthuis & Vlietland (Hospital)OTHER | 0 | Mar 19, 2026 | clinicaltrials |
| NCT07472868 | Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer(MEND-IT II) | not yet recruiting | Phase 3 | 394 | J. W. A. BurgerOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07464327 | A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | not yet recruiting | Phase 3 | 450 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Mar 11, 2026 | clinicaltrials |
| NCT07461675 | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection | not yet recruiting | Phase 3 | 30 | University of Geneva, SwitzerlandOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07442565 | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ(SYNSTAR03) | not yet recruiting | Phase 3 | 506 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 4, 2026 | clinicaltrials |
| NCT07446335 | A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 578 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07432087 | Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 246 | Yue He, MDOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07407517 | Adjuvant Intensification for LAR(POLARIS) | not yet recruiting | Phase 3 | 904 | Fudan UniversityOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07392866 | A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 120 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07383116 | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 500 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07384377 | JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan | not yet recruiting | Phase 3 | 123 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07385079 | Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 412 | Sun Yat-sen UniversityOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT06952621 | Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma(TD-NEOE3V3) | not yet recruiting | Phase 3 | 390 | Tang-Du HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07371897 | Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial(SHINE) | not yet recruiting | Phase 3 | 154 | Sun Yat-sen UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07373990 | Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 418 | Sun Yat-sen UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07366840 | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure(BRIGHT) | not yet recruiting | Phase 2 / Phase 3 | 268 | Fudan UniversityOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07356037 | Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 68 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07332533 | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | not yet recruiting | Phase 2 / Phase 3 | 490 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Jan 12, 2026 | clinicaltrials |
| NCT07328919 | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | not yet recruiting | Phase 3 | 138 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07320690 | De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma(Neo-Margin) | not yet recruiting | Phase 3 | 356 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07309419 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma(Cocktail-001) | not yet recruiting | Phase 2 / Phase 3 | 222 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07268690 | Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study | not yet recruiting | Phase 3 | 340 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07242274 | Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC | not yet recruiting | Phase 3 | 472 | JemincareINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 29, 2026source: clinicaltrials